Global Health Limited will host a virtual analyst meeting on August 21, 2026, as part of its ongoing engagement with institutional investors. The company disclosed the schedule in a filing dated August 18, 2026, confirming that management will participate in a one-to-one session with First Ray Capital based in Singapore.

The interaction is structured as a standard investor dialogue rather than a broad conference call. Global Health Limited emphasized that no unpublished price-sensitive information (UPSI) is proposed to be shared during the discussion. This aligns with regulatory norms requiring equal information access for all market participants.

Meeting Details

The specific parameters of the scheduled engagement are outlined below:

Rahul Ranjan, Company Secretary and Compliance Officer at Global Health Limited, signed the intimation. He noted that the schedule remains subject to change in the event of unforeseen circumstances involving the analysts, investors, or the company.

Regulatory Context

The disclosure was made pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This regulation mandates timely disclosure of material events and ensures transparency in interactions between listed entities and financial intermediaries.

Global Health Limited listed this update under reference number GHL/2026-27/EXCH/41. The filing was directed to the listing departments of both the BSE Limited and the National Stock Exchange of India Limited.

Global Health reported a record consolidated total income of ₹13,262 million for the quarter ended June 30, 2026 (Q1FY27), driven by robust patient volume growth and improved realizations. The company’s Board approved the unaudited standalone and consolidated financial results on July 30, 2026, fixing August 14, 2026, as the record date for a proposed final dividend of ₹0.50 per share for FY26. This dividend is subject to shareholder approval at the 22nd Annual General Meeting (AGM) scheduled for September 16, 2026. During the earnings call held on July 31, 2026, management highlighted that the Noida facility is achieving EBITDA breakeven earlier than expected, with losses narrowing significantly.

Statutory Auditors M/s Walker Chandiok & Co LLP issued limited review reports on the results pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. In strategic developments, the Board approved scaling up the Guwahati project to a 650-bed super-specialty hospital with a total capex of ₹9,700 million, funded through internal accruals and debt. Additionally, Mr. Pradeep Kumar Singh was appointed as Chief Digital Officer and Senior Management Personnel effective July 30, 2026.

Financial Performance

Consolidated revenue from operations grew 26.5% year-on-year to ₹13,041 million, up from ₹10,308 million in Q1FY26. Total income reached an all-time quarterly high of ₹13,262 million. While top-line growth was robust, consolidated net profit after tax (PAT) declined slightly by 1.1% to ₹1,573 million. This decline was primarily due to the absence of a non-recurring exceptional income of ₹196 million recorded in Q1FY26 from the reversal of potential interest liability on Export Promotion Capital Goods (EPCG) license transfer. Consolidated EBITDA rose 23.5% to ₹3,153 million.

Employee benefits expense surged 33.3% to ₹5,136 million, reflecting ongoing investments in human capital. Finance costs nearly doubled to ₹267 million from ₹138 million in Q1FY26. The Noida hospital contributed ₹855 million in total income but reported an EBITDA loss of ₹49 million, a significant improvement from the ₹236 million loss in Q4FY26.

Operational Highlights and Cluster Performance

Patient volumes drove the revenue growth, with in-patient counts increasing by 27.7% and out-patient counts rising by 34.5% year-on-year. Operational bed census increased 22.1% to 3,037 beds. Occupancy rate was 62.6%, down 53 basis points from 63.2% in Q1FY26, though occupancy excluding Noida remained healthy at 66%. Average Revenue Per Occupied Bed (ARPOB) rose 5.5% to ₹70,244, aided by a reduction in Average Length of Stay (ALOS) from 3.03 days to 2.87 days. International patient revenue grew 23.0% to ₹782 million, while OPD pharmacy revenue jumped 50.9% to ₹609 million.

Management introduced new cluster reporting. Cluster 1 (Gurugram, Indore, Ranchi) saw revenue grow 10% YoY to ₹7,715 million, with EBITDA margins improving to 24.1%. Cluster 2 (Lucknow, Patna, Noida) delivered 55% YoY revenue growth to ₹4,983 million. Excluding Noida, Cluster 2 achieved 28% revenue growth and 40% EBITDA growth with a margin of 32%. Average Revenue Per Patient (ARPP) stood at ₹201,891 for the quarter, broadly similar to the prior year.

Strategic Expansions and Capex Plan

The Guwahati expansion aims to serve over 50 million people in Assam and neighboring states. During the quarter, the company added 72 beds across its network, with 51 beds in Noida and 21 in Lucknow. It also onboarded over 70 doctors, including more than 50 senior clinicians, to strengthen clinical capabilities. Medanta Lucknow performed over 1,000 joint replacements using robotic technology during the quarter.

Looking ahead, Global Health has outlined a total capex plan of approximately ₹48,500 million for the next five years. This includes maintenance capex estimated at ₹6,000 million over the next three years. Key upcoming projects include a 400-bed hospital in South Delhi in partnership with DLF, a ~750-bed hospital in Pitampura, New Delhi, and land acquisition for a facility in Mumbai. An 80-bed cancer unit in Indore is expected to be operationalized in Q2/Q3 FY27.

What the Numbers Show

The divergence between record top-line growth and a slight dip in net profit underscores the impact of non-recurring items on bottom-line metrics. While Q1FY26 benefited from a ₹196 million EPCG license reversal, Q1FY27’s PAT reflects core operational performance. The contraction in consolidated EBITDA margins despite volume growth indicates that cost inflation, particularly in employee benefits, is outpacing revenue gains. However, the improving trajectory of the Noida unit and robust international patient revenue suggest underlying operational strength. The company’s aggressive expansion strategy, adding nearly 3,000 beds across five greenfield projects, positions it for long-term scale, though near-term margin pressure remains a key watchpoint.